An experimental gene therapy developed by the small biotech Avrobio (AVRO) reduced a type of fat that builds up to toxic levels in the cells and organs of patients with Fabry disease, the company reported Wednesday.

The newly presented clinical trial data were culled from just three patients born with the rare and sometimes deadly disease. Still, Avrobio believes the new data could start to alleviate concerns about the durability of the one-time gene therapy that surfaced last fall and ravaged the biotech’s stock price.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy